MoleculeMind, an AI protein design platform, has secured over $100 million in Series A funding. The investment, led by Blue Horizon Capital and Pudong Venture Capital, signals a shift in the AI for Science sector towards industrial-scale applications and commercial viability. The company leverages its proprietary AI operating system, MoleculeOS, and its foundational model, NewOrigin, to move beyond basic structure prediction into programmable bioengineering, demonstrating significant advancements in drug discovery and industrial enzyme modification. AI
IMPACT This funding round signifies a major investment in AI for Science, potentially accelerating the development and commercialization of AI-driven solutions in drug discovery and bioengineering.
RANK_REASON Significant funding round for an AI company in the AI for Science sector. [lever_c_demoted from significant: ic=1 ai=0.7]
- AlphaFold 3
- Blue Horizon Capital
- CaiXin Capital
- COFCO Emerging Industry Fund
- Fosun Capital
- Guofang Venture Capital
- Infinity Capital
- Kaisai Biological
- MMDesign
- MMFold
- MoleculeMind
- MoleculeOS
- NewOrigin
- Oriental Fortune Capital
- Pudong Venture Capital
- SaiFen Technology
- Xinhang Capital
- Xu Jinbo
- ZhengDing Capital
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
